DK1677777T3 - Pellets indeholdende venlafaxin-hydrochlorid - Google Patents

Pellets indeholdende venlafaxin-hydrochlorid

Info

Publication number
DK1677777T3
DK1677777T3 DK04791654T DK04791654T DK1677777T3 DK 1677777 T3 DK1677777 T3 DK 1677777T3 DK 04791654 T DK04791654 T DK 04791654T DK 04791654 T DK04791654 T DK 04791654T DK 1677777 T3 DK1677777 T3 DK 1677777T3
Authority
DK
Denmark
Prior art keywords
weight
pellets
venlafaxine hydrochloride
pellets containing
chloride
Prior art date
Application number
DK04791654T
Other languages
English (en)
Inventor
Pal Fekete
Ly Tibor Korb
Eszter Moricz
Agnes Bozso
Original Assignee
Egis Gyogyszergyar Nyrt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Egis Gyogyszergyar Nyrt filed Critical Egis Gyogyszergyar Nyrt
Application granted granted Critical
Publication of DK1677777T3 publication Critical patent/DK1677777T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1611Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5021Organic macromolecular compounds
    • A61K9/5026Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK04791654T 2003-10-10 2004-10-08 Pellets indeholdende venlafaxin-hydrochlorid DK1677777T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU0303382A HUP0303382A2 (hu) 2003-10-10 2003-10-10 Venlafaxin-hidroklorid-tartalmú pelletek
PCT/HU2004/000095 WO2005034930A1 (en) 2003-10-10 2004-10-08 Pellets containing venlafaxine hydrochloride

Publications (1)

Publication Number Publication Date
DK1677777T3 true DK1677777T3 (da) 2007-09-03

Family

ID=90001704

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04791654T DK1677777T3 (da) 2003-10-10 2004-10-08 Pellets indeholdende venlafaxin-hydrochlorid

Country Status (23)

Country Link
EP (1) EP1677777B1 (da)
CN (1) CN1882321B (da)
AT (1) ATE359771T1 (da)
AU (1) AU2004280132B2 (da)
BG (1) BG109539A (da)
CY (1) CY1106693T1 (da)
CZ (1) CZ2006269A3 (da)
DE (1) DE602004006009T2 (da)
DK (1) DK1677777T3 (da)
EA (1) EA009695B1 (da)
ES (1) ES2285538T3 (da)
HK (1) HK1098364A1 (da)
HR (2) HRP20060136A2 (da)
HU (1) HUP0303382A2 (da)
IL (1) IL174830A (da)
NO (1) NO20062082L (da)
PL (2) PL1677777T3 (da)
PT (1) PT1677777E (da)
RS (2) RS52150B (da)
SI (1) SI1677777T1 (da)
SK (1) SK50442006A3 (da)
UA (1) UA82268C2 (da)
WO (1) WO2005034930A1 (da)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
ATE526950T1 (de) 1999-10-29 2011-10-15 Euro Celtique Sa Hydrocodon-formulierungen mit gesteuerter freisetzung
EP2263658A1 (en) 2000-10-30 2010-12-22 Euro-Celtique S.A. Controlled release hydrocodone formulations
IL146462A (en) 2001-11-13 2015-02-26 Lycored Bio Ltd Prolonged-release preparations containing as an active compound and analapaxin hydrochloride
WO2007016315A2 (en) * 2005-07-28 2007-02-08 Dr. Reddy's Laboratories Ltd. Extended release venlafaxine compositions
EP2023903B1 (en) * 2006-05-19 2014-04-23 EGIS Gyógyszergyár Nyilvánosan Müködõ Részvénytársaság Process for the preparation and surface coating of pellets
US8445018B2 (en) 2006-09-15 2013-05-21 Cima Labs Inc. Abuse resistant drug formulation
JP2013526523A (ja) 2010-05-11 2013-06-24 シマ ラブス インク. メトプロロールを含むアルコール耐性持続放出性経口剤形
MX2012013023A (es) * 2010-05-11 2012-12-17 Cima Labs Inc Formas de dosificacion de liberacion prolongada resistentes ala alcohol y que comprenden venlafaxina.
WO2014096124A1 (en) * 2012-12-19 2014-06-26 Ratiopharm Gmbh Film coated pellets
CN103893151B (zh) * 2012-12-31 2018-04-27 石药集团中奇制药技术(石家庄)有限公司 一种盐酸文拉法辛缓释胶囊及其制备方法
US20150118300A1 (en) 2013-10-31 2015-04-30 Cima Labs Inc. Immediate Release Abuse-Deterrent Granulated Dosage Forms
US20220062200A1 (en) 2019-05-07 2022-03-03 Clexio Biosciences Ltd. Abuse-deterrent dosage forms containing esketamine
EP3965733A4 (en) 2019-05-07 2023-01-11 Clexio Biosciences Ltd. ABUSE DETERRENT DOSAGE FORMS CONTAINING ESKETAMINE
CN114028577B (zh) * 2021-10-20 2024-07-02 珠海市东辰制药有限公司 一种二氧化硅丸芯及其制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE57198A1 (es) * 1996-03-25 1998-10-10 American Home Prod Formula de liberacion prolongada
EP1331003B1 (en) * 1996-03-25 2015-08-26 Wyeth LLC Extended release formulation containing venlafaxine
UA77145C2 (en) * 1997-11-05 2006-11-15 Wyeth Corp Extended release dosage formulation
CN1334080A (zh) * 2001-07-25 2002-02-06 成都康弘制药有限公司 盐酸万拉法新缓释片及其制备方法
IL146462A (en) * 2001-11-13 2015-02-26 Lycored Bio Ltd Prolonged-release preparations containing as an active compound and analapaxin hydrochloride
AU2003219117A1 (en) * 2002-03-28 2003-10-13 Synthon B.V. Extended release venlafaxine formulations

Also Published As

Publication number Publication date
PT1677777E (pt) 2007-06-21
HUP0303382A2 (hu) 2005-08-29
ATE359771T1 (de) 2007-05-15
EP1677777B1 (en) 2007-04-18
HRP20060136A2 (en) 2006-06-30
HRP20070322T3 (en) 2007-09-30
CY1106693T1 (el) 2012-05-23
AU2004280132A1 (en) 2005-04-21
DE602004006009T2 (de) 2008-01-10
CZ2006269A3 (cs) 2006-07-12
CN1882321A (zh) 2006-12-20
NO20062082L (no) 2006-05-09
HK1098364A1 (en) 2007-07-20
SK50442006A3 (sk) 2006-08-03
DE602004006009D1 (de) 2007-05-31
RS52150B (en) 2012-08-31
ES2285538T3 (es) 2007-11-16
EA009695B1 (ru) 2008-02-28
PL379541A1 (pl) 2006-10-02
EP1677777A1 (en) 2006-07-12
UA82268C2 (uk) 2008-03-25
EA200600675A1 (ru) 2006-08-25
CN1882321B (zh) 2011-06-08
RS20060252A (en) 2008-08-07
WO2005034930A1 (en) 2005-04-21
AU2004280132B2 (en) 2009-10-22
HUP0303382D0 (en) 2003-12-29
IL174830A (en) 2010-04-15
IL174830A0 (en) 2008-04-13
BG109539A (bg) 2006-11-30
SI1677777T1 (sl) 2007-10-31
PL1677777T3 (pl) 2007-08-31

Similar Documents

Publication Publication Date Title
HK1098364A1 (en) Pellets containing venlafaxine hydrochloride
RS52169B (en) STABLE LAKVINIMOD PREPARATIONS
EA200700049A1 (ru) Препаративные формы оральных лекарственных форм мемантина с модифицированным высвобождением
SG153830A1 (en) Galenic formulations of organic compounds
MX2010013766A (es) Rasagilina para modificacion de enfermedad de parkinson.
SG158168A1 (en) 5ht2c receptor modulator compositions and methods of use
ES2530719T3 (es) Formulaciones de oxicodona para ser administradas una vez al día
WO2009028495A1 (ja) 真菌性皮膚炎用剤
NO341573B1 (no) Faste formuleringer av ospemifen og fremgangsmåte for fremstilling av ospemifen
JO2973B1 (en) Fumarate salt for (alpha-beta-R) -6-bromo-alpha-[2- (methylamino) ethyl-2-methoxy-alpha-1-naphthalenyl-beta-phenyl-3-quinoline ethanol
NO20063809L (no) Belagte minitabletter av venlaflaxin hydroklorid med forlenget virkning
MY139086A (en) Use of debranched starch in extrusion-spheronization pharmaceutical pellets
EA200702496A1 (ru) Местная композиция, содержащая желатин
JP2011516544A5 (da)
NO20051261L (no) Morfin-6-glukuronidsalt
MX2010003594A (es) Formas cristalinas de sal sodica de dmxaa.
SG170037A1 (en) Compositions useful for reducing nephrotoxicity and methods of use thereof
GR1004331B (el) Νεες φαρμακευτικες συνθεσεις που περιεχουν αλας αλενδρονικου οξεος
RU2006126471A (ru) Способ лечения воспалительных заболеваний слюнных желез
TW200631600A (en) Hair fitness/body improving agent and hair cosmetic
TNSN06242A1 (en) Extended release coated minitablets of venlafaxine hydrochloride
MY134311A (en) Medicament with delayed active constituent release containing 1-dimethylamino-3-(3-methoxyphenyl)-2-methylpentan-3-ol
WO2005115092A3 (en) Micronized oral pharmaceutical composition
JO2440B1 (en) Formulation of oral pharmaceutical polymers for controlled release of terbutalate sulfate.